Products for Research Use Only

Navarixin

CAT: 0804-HY-10198-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10198-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly[1][2].
CAS Number
473727-83-2
Product Name Alternative
SCH 527123; MK-7123
UNSPSC
12352005
Hazard Statement
H302, H372, H410
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Endocrinology; Cancer
Assay Protocol
https://www.medchemexpress.com/SCH-527123.html
Concentration
10mM
Purity
99.33
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C1C(C(NC2=CC=CC(C(N(C)C)=O)=C2O)=C1N[C@H](CC)C3=CC=C(O3)C)=O
Molecular Formula
C21H23N3O5
Molecular Weight
397.42
Precautions
H302, H372, H410
References & Citations
[1]Gonsiorek W, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther. 2007 Aug;322 (2) :477-85.|[2]Chapman RW, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther. 2007 Aug;322 (2) :486-93.|[3]Ning Y, et al. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to NSC 266046 in preclinical colon cancer models. Mol Cancer Ther. 2012 Jun;11 (6) :1353-64.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CXCR1; CXCR2